Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia

Acta Haematologica

Volumn 112, Issue 1-2, 2004, Pages 55-67

  Reiter, Andreas ^a   Lengfelder, Eva ^a   Grimwade, David ^b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Acute promyelocytic leukaemia; Promyelocytic leukaemia; Retinoic acid receptor alpha

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 17Q; DISEASE COURSE; DNA DAMAGE; DNA RECOMBINATION; DNA REPAIR; GENE DELETION; GENE DUPLICATION; HIGH RISK POPULATION; HUMAN; INTRON; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL;

HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM, RESIDUAL; RECEPTORS, RETINOIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 2642561788     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077560     Document Type: Review

References (114)

1. Grimwade D: The pathogenesis of acute promyelocytic leukaemia: Evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999;106:591-613.
2. Berger R, Bernheim A, Daniel MT, Valensi F, Flandrin G: Karyotype and cell phenotypes in primary acute leukemias. Blood Cells 1981;7/2:287-292.
3. Davey FR, Davis RB, MacCallum JM, Nelson DA, Mayer RJ, Ball ED, Griffin JD, Schiffer CA, Bloomfield CD: Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol 1989;30/4:221-227.
4. Fenaux P, Chomienne C, Degos L: Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2001;14/1:153-174.
5. Tallman MS, Nabhan C, Feusner JH, Rowe JM: Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 2002;99:759-767.
6. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F: All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 1992;80:2176-2181.
7. Ohno R, Yoshida H, Fukutani H, Naoe T, Ohshima T, Kyo T, Endoh N, Fujimoto T, Kobayashi T, Hiraoka A: Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare. Leukemia 1993;7:1722-1727.
8. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241-3249.
9. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995;85:1202-1206.
10. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F: Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997;90:1014-1021.
11. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-1028.
12. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial. Blood 1999;93:4131-4143.
13. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192-1200.
14. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, Bolufer P, Barragan E, Terol MJ, Gonzalez JD, Colomer D, Chillon C, Rivas C, Gomez T, Ribera JM, Bornstein R, Roman J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Deben G: A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999;94:3015-3021.
15. Lengfelder E, Reichert A, Schoch C, Haferlach T, Löffler H, Staib P, Heyll A, Seifarth W, Saussele S, Fonatsch C, Gassmann W, Ludwig WD, Hochhaus A, Beelen D, Aul C, Sauerland MC, Heinecke A, Hehlmann R, Wörmann B, Hiddemann W, Büchner T: Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000;14:1362-1370.
16. Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, Sanz M, Link H, Maloisel F, Gardin C, Bordessoule D, Stoppa AM, Sadoun A, Muus P, Wandt H, Mineur P, Whittaker JA, Fey M, Daniel MT, Castaigne S, Degos L: Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000;14:1371-1377.
17. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-4302.
18. Fenaux P, Chomienne C, Degos L: Acute promyelocytic leukemia: Biology and treatment. Semin Oncol 1997;24/1:92-102.
19. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
20. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-1348.
21. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang T, Waxman S, Wang ZY, Chen SJ, Hu J, Shen ZX, Chen SJ: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-3324.
22. Huan SY, Yang CH, Chen YC: Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: An useful salvage therapy. Leuk Lymphoma 2000;38/3-4:283-293.
23. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-3860.
24. Lo Coco F: Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia. Haematologica 2002;87:452-453.
25. Jurcic JG, Caron PC, Miller WH Jr, Yao TJ, Maslak P, Finn RD, Larson SM, Warrell RP Jr, Scheinberg DA: Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 1995;9/2:244-248.
26. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA: Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000;6:372-380.
27. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM: Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99:4222-4224.
28. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998;90:1621-1625.
29. Kitamura K, Hoshi S, Koike M, Kiyoi H, Saito H, Naoe T: Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br J Haematol 2000;108:696-702.
30. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351:700-708.
31. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G: The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385-400.
32. Rowley JD, Golomb HM, Dougherty C: 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977;1:549-550.
33. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD: Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827-841.
34. Borrow J, Goddard AD, Sheer D, Solomon E: Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249:1577-1580.
35. De The H, Chomienne C, Lanotte M, Degos L, Dejean A: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990;347:558-561.
36. Alcalay M, Zangrilli D, Pandolfi PP, Longo L, Mencarelli A, Giacomucci A, Rocchi M, Biondi A, Rambaldi A, Lo Coco F: Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci USA 1991;88:1977-1981.
37. De The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A: The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66:675-684.
38. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, Dmitrovsky E, Evans RM: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991;66:663-674.
39. Goddard AD, Borrow J, Freemont PS, Solomon E: Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991;254:1371-1374.
40. Lo Coco F, Diverio D, D'Adamo F, Avvisati G, Alimena G, Nanni M, Alcalay M, Pandolfi PP, Pelicci PG: PML/RAR-alpha rearrangement in acute promyelocytic leukaemias apparently lacking the t(15;17) translocation. Eur J Haematol 1992;48/3:173-176.
41. Borrow J, Shipley J, Howe K, Kiely F, Goddard A, Sheer D, Srivastava A, Antony AC, Fioretos T, Mitelman F: Molecular analysis of simple variant translocations in acute promyelocytic leukemia. Genes Chromosomes Cancer 1994;9/4:234-243.
42. Hiorns LR, Min T, Swansbury GJ, Zelent A, Dyer MJ, Catovsky D: Interstitial insertion of retinoic acid receptor-alpha gene in acute promyelocytic leukemia with normal chromosomes 15 and 17. Blood 1994;83:2946-2951.
43. Lafage-Pochitaloff M, Alcalay M, Brunel V, Longo L, Sainty D, Simonetti J, Birg F, Pelicci PG: Acute promyelocytic leukemia cases with nonreciprocal PML/RARa or RARa/PML fusion genes. Blood 1995;85:1169-1174.
44. Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E: Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: Cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996;94:557-573.
45. Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E: Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997;90:4876-4885.
46. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, Howe K, Dastugue N, Jansen J, Radford-Weiss I, Lo Coco F, Lessard M, Hernandez JM, Delabesse E, Head D, Liso V, Sainty D, Flandrin G, Solomon E, Birg F, Lafage-Pochitaloff M: Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): Results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action 'Molecular Cytogenetic Diagnosis in Haematological Malignancies'. Blood 2000;96:1297-1308.
47. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A: Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993;12:1161-1167.
48. Chen SJ, Zelent A, Tong JH, Yu HQ, Wang ZY, Derre J, Berger R, Waxman S, Chen Z: Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest 1993;91:2260-2267.
49. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ: The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996;87:882-886.
50. Wells RA, Catzavelos C, Kamel-Reid S: Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 1997;17/1:109-113.
51. Arnould C, Philippe C, Bourdon V, Grégoire MJ, Berger R, Jonveaux P: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 1999;8:1741-1749.
52. Melnick A, Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-3215.
53. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD: Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 2001;20:7186-7203.
54. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995;85:1083-1094.
55. Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, De The H: Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 1999;18:1113-1118.
56. Sainty D, Liso V, Cantu-Rajnoldi A, Head D, Mozziconacci MJ, Arnoulet C, Benattar L, Fenu S, Mancini M, Duchayne E, Mahon FX, Gutierrez N, Birg F, Biondi A, Grimwade D, Lafage-Pochitaloff M, Hagemeijer A, Flandrin G: A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Group Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Acion 'Molecular Cytogenetic Diagnosis in Haematological Malignancies'. Blood 2000;96:1287-1296.
57. Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y: Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Exp Hematol 2001;29:864-872.
58. Chillon MC, Gonzalez M, Garcia-Sanz R, Balanzategui A, Gonzalez D, Lopez-Perez R, Mateos MV, Alaejos I, Rayon C, Arbeteta J, Hernandez JM, Orfao A, San Miguel J: Two new 3′ PML breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. Genes Chromosomes Cancer 2000;27:35-43.
59. Barragan E, Bolufer P, Martin G, Cervera J, Moreno I, Capote FJ, Rosique P, Sanz MA: Identification of two atypical PML-RAR(alpha) transcripts in two patients with acute promyelocytic leukemia. Leuk Res 2002;26:439-442.
60. Pandolfi PP, Alcalay M, Longo L, Fagioli M, Zangrilli D, Grignani F, Mencarelli A, Biondi A, Rambaldi A, Lo Coco F: Molecular genetics of the t(15;17) of acute promyelocytic leukemia (APL). Leukemia 1992;6(suppl 3):120S-122S.
61. Gallagher RE, Li YP, Rao S, Paietta E, Andersen J, Etkind P, Bennett JM, Tallman MS, Wiernik PH: Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6:Identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 1995;86:1540-1547.
62. Kane JR, Head DR, Balazs L, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Behm FG, Krance RA, Shurtleff SA, Downing JR: Molecular analysis of the PML/RAR alpha chimeric gene in pediatric acute promyelocytic leukemia. Leukemia 1996;10:1296-1302.
63. Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE: Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: Results from intergroup protocol 0129. Blood 2000;95:398-403.
64. Gu BW, Xiong H, Zhou Y, Chen B, Wang L, Dong S, Yu ZY, Lu LF, Zhong M, Yin HF, Zhu GF, Huang W, Ren SX, Gallagher RE, Waxman S, Chen GQ, Wang ZG, Chen Z, Fu G, Chen SJ: Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: Use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proc Natl Acad Sci USA 2002;99:7640-7645.
65. Reiter A, Saussele S, Grimwade D, Wiemels JL, Segal MR, Lafage-Pochitaloff M, Walz C, Weisser A, Hochhaus A, Willer A, Reichert A, Büchner T, Lengfelder E, Hehlmann R, Cross NCP: Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer 2003;36/2:175-188.
66. Kastner P, Chan S: Function of RARalpha during the maturation of neutrophils. Oncogene 2001;20:7178-7185.
67. Piazza F, Gurrieri C, Pandolfi PP: The theory of APL. Oncogene 2001;20:7216-7222.
68. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG: Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002;295:1079-1082.
69. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H: Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001;7:680-686.
70. Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ: Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 2000;97:13306-13311.
71. Le Beau MM, Bitts S, Davis EM, Kogan SC: Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 2002;99:2985-2991.
72. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, Ley TJ, Gilliland DG: PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002;99:8283-8288.
73. Le Beau MM, Davis EM, Patel B, Phan VT, Sohal J, Kogan SC: Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia. Blood 2003;102:1072-1074.
74. Mistry AR, Wessel Pedersen E, Solomon E, Grimwade D: The molecular pathogenesis of acute promyelocytic leukaemia: Implications for the clinical management of the disease. Blood Rev 2003;17/2:71-97.
75. Dyck JA, Warrell RP Jr, Evans RM, Miller WH Jr: Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. Blood 1995;86:862-867.
76. Schoch C, Schnittger S, Kern W, Lengfelder E, Loffler H, Hiddemann W, Haferlach T: Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia. Hematology J 2002;3/5:259-263.
77. Miller WH Jr, Kakizuka A, Frankel SR, Warrell RP Jr, DeBlasio A, Levine K, Evans RM, Dmitrovsky E: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992;89:2694-2698.
78. Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Fioretos T, Dube I, Winfield DA, Kingston J, Hagemeijer A: Diagnosis of acute promyelocytic leukaemia by RT-PCR: Detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 1992;82:529-540.
79. Huang W, Sun GL, Li XS, Cao Q, Lu Y, Jang GS, Zhang FQ, Chai JR, Wang ZY, Waxman S: Acute promyelocytic leukemia: Clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993;82:1264-1269.
80. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH: Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood 1997;90:1656-1663.
81. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr: Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 2001;98:2651-2656.
82. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E: Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 1996;10/1:61-66.
83. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM, Biondi A, Rossi G, Carlo-Stella C, Selleri C, Martino B, Specchia G, Mandelli F: Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999;94:2225-2229.
84. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998;16/1:78-85.
85. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Diaz-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-1253.
86. Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC: CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome? J Clin Oncol 1999;17/1:293-297.
87. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L, Lo Coco F: CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000;18:1295-1300.
88. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-1759.
89. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G, Mandelli F, Grignani F, Masera G, Barbui T: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992;340:1437-1438.
90. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RARalpha fusion mRNA. Blood 1993;82:1689-1694.
91. Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, Miyake T, Nakayama Y, Kobayashi H, Goto S, Takeshita A, Kobayashi S, Kato Y, Shiraishi K, Sasada M, Ohtake S, Murakami H, Kobayashi M, Endo N, Shindo H, Matsushita K, Hasegawa S, Tsuji K, Ueda Y, Tominaga N, Furuya H, Inoue Y, Takeuchi J, Morishita H, Iida H: Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1995;9:1478-1482.
92. Seale JR, Varma S, Swirsky DM, Pandolfi PP, Goldman JM, Cross NC: Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: Explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. Br J Haematol 1996;95/1:95-101.
93. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. Blood 1998;92:784-789.
94. Gameiro P, Vieira S, Carrara P, Silva AL, Diamond J, Botelho S de, Mehta AB, Prentice HG, Guimaraes JE, Hoffbrand AV, Foroni L, Parreira A: The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients. Haematologica 2001;86:577-585.
95. Lo Coco F, Romano A, Mencarelli A, Diverio D, Iori AP, Moleti ML, de Santis S, Cerretti R, Mandelli F, Arcese W: Allogeneic stem cell transplantation for advanced APL: Results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 2003;17:1930-1933.
96. Devaraj PE, Foroni L, Prentice HG, Hoffbrand VA, Secker-Walker LM: Relapse of acute promyelocytic leukemia follows serial negative RT-PCR assays: A cautionary tale. Leuk Res 1996;20:733-737.
97. Lo Coco F, De Santis S, Esposito A, Divona M, Diverio D: Molecular monitoring of hematologic malignancies: Current and future issues. Semin Hematol 2002;39(2 suppl 1):14-17.
98. Tobal K, Liu Yin JA: RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia 1998; 12:1349-1354.
99. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ: Standardization and quality control studies of 'real time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-2357.
100. Tobal K, Moore H, Macheta M, Yin JA: Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RT-PCR method. Leukemia 2001;15:1060-1065.
101. Müller MC, Merx K, Weisser A, Kreil S, Lahaye T, Hehlmann R, Hochhaus A: Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia 2002;16:2395-2399.
102. Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, Mandelli F, Lo Coco F: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997;90:1321-1325.
103. Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P: Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia 2000;14:1006-1013.
104. Roman J, Martin C, Torres A, Jimenez MA, Andres P, Flores R, de la Torre MJ, Sanchez J, Serrano J, Falcon M: Absence of detectable PML-RAR alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplant 1997;19:679-683.
105. Takatsuki H, Umemura T, Sadamura S, Yamashita S, Goto T, Abe Y, Yufu Y, Inaba S, Nishimura J, Nawata H: Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RAR alpha fusion mRNA: A study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation. Leukemia 1995;9:889-892.
106. Lengfelder E, Gnad U, Büchner T, Hehlmann R: Treatment of relapsed acute promyelocytic leukemia. Onkologie 2003;26:373-379.
107. Grimwade D, Jamal R, Goulden N, Kempski H, Mastrangelo S, Veys P: Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid. Br J Haematol 1998;103:559-562.
108. Tedeschi A, Cairoli R, Marenco P, Nosari A, Tresoldi E, Di Bona E, Montillo M, Morra E: Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation. Leukemia 2002;16:2455-2456.
109. Grigg A, Kimber R, Szer J: Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. Leukemia 2003;17:1916-1917.
110. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P, Degos L, Vidaud M, Chomienne C: Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000;14:324-328.
111. Visani G, Buonamici S, Malagola M, Isidori A, Piccaluga PP, Martinelli G, Ottaviani E, Grafone T, Baccarani M, Tura S: Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic
112. Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, Kim SH, Gallagher RE, Willman CL: Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn 2001;3/4:141-149.
113. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL: Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003;101:2521-2528.
114. Gu BW, Hu J, Xu L, Yan H, Jin WR, Zhu YM, Zhao WL, Niu C, Cao Q, Su XY, Gu J, Ying HY, Chen Y, Xiong SM, Shen ZX, Chen Z, Chen SJ: Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARalpha fusion transcript in patients with acute promyelocytic leukemia. Hematol J 2001;2:330-340.